Tagraxofusp (SL-401) is an anti-CD123 antibody conjugated to diphtheria toxin that has shown efficacy in the treatment of BPDCN [108]. This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.